176 related articles for article (PubMed ID: 23674072)
1. Downregulation of BMP6 enhances cell proliferation and chemoresistance via activation of the ERK signaling pathway in breast cancer.
Lian WJ; Liu G; Liu YJ; Zhao ZW; Yi T; Zhou HY
Oncol Rep; 2013 Jul; 30(1):193-200. PubMed ID: 23674072
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
3. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
4. Reduced BMP6 expression by DNA methylation contributes to EMT and drug resistance in breast cancer cells.
Liu G; Liu YJ; Lian WJ; Zhao ZW; Yi T; Zhou HY
Oncol Rep; 2014 Aug; 32(2):581-8. PubMed ID: 24890613
[TBL] [Abstract][Full Text] [Related]
5. [Expression and clinical significance of bone morphogenetic protein 6 in human breast cancer].
Liu G; Lian WJ; Zhou HY; Bie MJ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Mar; 45(2):249-53. PubMed ID: 24749350
[TBL] [Abstract][Full Text] [Related]
6. Over-expression of metallothionein predicts chemoresistance in breast cancer.
Yap X; Tan HY; Huang J; Lai Y; Yip GW; Tan PH; Bay BH
J Pathol; 2009 Mar; 217(4):563-70. PubMed ID: 19116991
[TBL] [Abstract][Full Text] [Related]
7. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
8. FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer.
Xu M; Chen S; Yang W; Cheng X; Ye Y; Mao J; Wu X; Huang L; Ji J
Cell Physiol Biochem; 2018; 47(1):151-160. PubMed ID: 29763898
[TBL] [Abstract][Full Text] [Related]
9. YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells.
Yang YF; Lee YC; Wang YY; Wang CH; Hou MF; Yuan SF
Kaohsiung J Med Sci; 2019 Jul; 35(7):408-416. PubMed ID: 31001932
[TBL] [Abstract][Full Text] [Related]
10. Ell3 stimulates proliferation, drug resistance, and cancer stem cell properties of breast cancer cells via a MEK/ERK-dependent signaling pathway.
Ahn HJ; Kim G; Park KS
Biochem Biophys Res Commun; 2013 Aug; 437(4):557-64. PubMed ID: 23850691
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of interferon-induced transmembrane protein 3 expression suppresses breast cancer cell growth and colony formation and affects the cell cycle.
Yang M; Gao H; Chen P; Jia J; Wu S
Oncol Rep; 2013 Jul; 30(1):171-8. PubMed ID: 23624618
[TBL] [Abstract][Full Text] [Related]
13. Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation.
Takahashi M; Otsuka F; Miyoshi T; Otani H; Goto J; Yamashita M; Ogura T; Makino H; Doihara H
J Endocrinol; 2008 Dec; 199(3):445-55. PubMed ID: 18780779
[TBL] [Abstract][Full Text] [Related]
14. CD24 enhances DNA damage-induced apoptosis by modulating NF-κB signaling in CD44-expressing breast cancer cells.
Ju JH; Jang K; Lee KM; Kim M; Kim J; Yi JY; Noh DY; Shin I
Carcinogenesis; 2011 Oct; 32(10):1474-83. PubMed ID: 21798852
[TBL] [Abstract][Full Text] [Related]
15. Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both Smad and p38 pathways.
Du J; Yang S; Wang Z; Zhai C; Yuan W; Lei R; Zhang J; Zhu T
J Cell Biochem; 2008 Apr; 103(5):1584-97. PubMed ID: 17879955
[TBL] [Abstract][Full Text] [Related]
16. Functional interaction of fibroblast growth factor-8, bone morphogenetic protein and estrogen receptor in breast cancer cell proliferation.
Masuda H; Otsuka F; Matsumoto Y; Takano M; Miyoshi T; Inagaki K; Shien T; Taira N; Makino H; Doihara H
Mol Cell Endocrinol; 2011 Aug; 343(1-2):7-17. PubMed ID: 21664418
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor potentiates mTORC2 signaling in breast cancer cells by upregulating superoxide anions.
Kumari Kanchan R; Tripathi C; Singh Baghel K; Kumar Dwivedi S; Kumar B; Sanyal S; Sharma S; Mitra K; Garg V; Singh K; Sultana S; Kamal Tripathi R; Kumar Rath S; Bhadauria S
Free Radic Biol Med; 2012 Nov; 53(10):1929-41. PubMed ID: 23000059
[TBL] [Abstract][Full Text] [Related]
18. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B
J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells.
Yang L; Wei L; Zhao W; Wang X; Zheng G; Zheng M; Song X; Zuo W
Mol Med Rep; 2012 Feb; 5(2):373-6. PubMed ID: 22143930
[TBL] [Abstract][Full Text] [Related]
20. The prognostic potential of keratin 18 in breast cancer associated with tumor dedifferentiation, and the loss of estrogen and progesterone receptors.
Ha SA; Lee YS; Kim HK; Yoo J; Kim S; Gong GH; Lee YK; Kim JW
Cancer Biomark; 2011; 10(5):219-31. PubMed ID: 22699783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
